Leiomyosarcoma Of Prostate Research Articles

Adult genitourinary sarcomas: A single-centre experience over 25 years.

e23532 Background: Genitourinary sarcomas are a rare entity. This study is a retrospective review of the patient characteristics, types of adult GU sarcomas, treatments and outcomes in a single institution over the past 25 years. Methods: Survival probabilities were estimated and plotted using the Kaplan-Meier method. Estimates along with 95% pointwise confidence intervals were reported. Recurrence-free survival (RFS) is defined as time from when the patient was disease-free to recurrence. Otherwise, patients were censored at last disease evaluation. OS was defined as time from when the patient was disease-free to death due to any cause. Patients still alive were censored at last known alive. Results: 29 patients presented with various types of GU sarcomas, with the majority being paratesticular tumors (n = 22, 75.9%). Others included bladder leiomyosarcomas (n = 5), prostatic leiomyosarcoma (n = 1), renal leiomyosarcoma (n = 1). Median age for diagnosis was 51 years (range: 21-79) for leiomyosarcoma vs 61 (range: 36-89) for liposarcoma. Among the paratesticular tumors majority were (n = 16) were liposarcoma, remaining 5 being leiomyosarcoma and 1 being rhabdomyosarcoma. Majority tumors were stage III and above (n = 16, 55.17%), high and intermediate grade (65.51%). All tumors were resected ± adjuvant therapy (n = 4). Leiomyosarcomas had a higher stage (66%) and grade (83%) at diagnosis, recurrence rate was also higher at 37.5% (vs 6.6% for liposarcoma) along with a higher mortality (41.6%). Commonest site of recurrence for leiomyosarcoma was the lungs (n = 3, 100%). Treatment for recurrence commonly involved radiotherapy, pembrolizumab etc. Paratesticular liposarcomas were found to be associated with a lipomatosis syndrome with n = 5 (31.25%) having lipomas elsewhere in the body and n = 2 (12.5%) patients having had previously resected spermatic cord lipoma. Paratesticular sarcomas often required (n = 15, 68%) revision surgery due to being initially diagnosed as a hernia, cord lipoma or hydrocele and requiring high ligation of the cord with hemiscrotectomy and radical orchiectomy ± LND on revision surgery, which often demonstrated a focus of residual tumor in liposarcomas (n = 5, 31%). N = 4 patients (25%) had positive margins in spite of revision surgery. Majority of these were MDM2+ positive on FISH (n = 9, 56%). Overall, GU sarcomas had an RFS of 63% (53-94%) and OS of 82% (53-94%) at 36 months since NED was achieved. The median length of follow-up was 19.9 months for leiomyosarcoma, 33.8 months for liposarcoma. Conclusions: Leiomyosarcomas in adults have worse outcomes compared to other GU sarcomas especially if it originates in the bladder. [Table: see text]

Leiomyosarcoma of Prostate: Case Report and Literature Review

Prostate sarcomas originate from the mesenchymal tissues including smooth muscle, fibromuscular stroma, paraganglia, nerves, and blood vessels. They account for less than 0.1% of all prostate tumors and often present with obstructive symptoms. It is an aggressive malignancy with a high risk of metastasis and a poor prognosis that poses unique diagnostic and treatment challenges. Histopathological examination is essential for definitive diagnosis, and can be performed at an early stage using guided transrectal prostate biopsy. Since prostate specific antigen levels are generally normal, digital rectal examinations are extremely important. We report on a 51-year-old man who was diagnosed with leiomyosarcoma based on the histopathology of his transurethral prostatectomy specimen.

Primary leiomyosarcoma of prostate: Report of 3 cases

Prostate sarcomas originate from the mesenchymal tissues including smooth muscle, fibromuscular stroma, paraganglia, nerves, and blood vessels. They account for less than 0.1% of all prostate tumors and often present with obstructive symptoms. Leiomyosarcoma is the most common sarcoma involving the prostate in adults affecting men between the ages of 40 and 78 years. Patients with leiomyosarcoma of the prostate commonly have a poor prognosis and their life expectancy depends on the stage of the disease at the initial diagnosis. Histopathological examination is essential for definitive diagnosis and can be performed at an early stage using guided transrectal prostate biopsy. Since prostate specific antigen (PSA) levels are generally normal, digital rectal examinations are extremely important. Tumor cells commonly express vimentin, smooth muscle actin and desmin, and up to 25% express cytokeratins. We report 3 cases of prostatic leiomyosarcoma with clinical, radiological, histopathological features and immunohistochemistry.

Prostate leiomyosarcoma: A rare tumor

Leiomyosarcoma is a rare neoplasm with a poor survival rate. Between June 2018 to January 2019 we treated a rare case of Prostate Leiomyosarcoma initially metastatic to the lung and the liver with multiple pelviclymph nodes. Five cycles of chemotherapy and palliative radiotherapy have been delivered with a mean follow up of 1 year .Chestabdominal-pelvic CT scan with MRI and bone scan are necessarily to assess clinical staging. The objective of this study is to review our experience in the management of Prostate Leiomyosarcoma at the Casablanca Cancer Center of Mohammed VI University of Health Sciences with a literature review of this rare neoplasm.

Prostate leiomyosarcoma: A rare tumor

Prostate leiomyosarcoma: A rare tumor

Prostate leiomyosarcoma treatment using three-dimensional reconstruction: a case report and literature review

Background: Prostate sarcoma is a malignant tumor from the prostate stroma. However, its pathogenesis is unknown. This is a rare type of prostate tumor. Case Presentation: A rare case of prostate leiomyosarcoma has been described. A 55-year-old prostate leiomyosarcoma patient who suffered from progressive dysuria and frequent urination for half a year was examined. Pathology, immunohistochemical staining, and laparoscopic radical prostatectomy were performed using three-dimensional (3D) reconstruction to diagnose prostate leiomyosarcoma. The patient did not receive adjuvant therapy after the operation. Final pathology was used to confirm prostate leiomyosarcoma. After one year of follow-up, the patient regularly underwent a digital rectal examination and abdominal MRI. However, no tumor recurrence or metastasis was found. Discussion: We discussed diagnosis and treatment of prostate leiomyosarcoma and reviewd literatures. Conclusion: Prostate leiomyosarcoma is a rare special type of prostate tumor, and its diagnosis is mainly based on pathological features. Radical excision is the primary treatment for prostate leiomyosarcoma. The 3D reconstruction is essential in the surgery because it can determine the size of the tumor and its relationship to the surrounding tissue. A postoperative adjuvant therapy can also be performed.

A rare case of leiomyosarcoma of the prostate: Treatment and review of literature

Leiomyosarcoma is most common in adults and constitutes 38%–52% of primary prostatic sarcomas. Primary prostatic leiomyosarcoma is extremely rare which accounts for 0.1% of all prostatic malignancies. Patients present with signs and symptoms generally encountered with prostatic enlargement. A 41-year-old gentleman presented with complaints of burning micturition and difficulty in passing urine and stools for 1 month. Magnetic resonance imaging of the pelvis showed a 10 cm × 5.6 cm × 5.9 cm heterogeneous mass lesion originating from the prostate gland extending into bilateral seminal vesicles. There is loss of fat planes with bladder, rectum, and rectosigmoid. Transrectal ultrasound-guided biopsy and immunohistochemistry confirmed the diagnosis as leiomyosarcoma of the prostate. Because of the proximity of the prostate with urinary bladder and difficulty in resection, the patient received neoadjuvant stereotactic body radiotherapy (SBRT) to a dose of 30 Gy in 5 fractions alternate day over a period of 2 weeks. The patient underwent cystoscopy, followed by radical prostatectomy 1 month post-SBRT. Histopathological examination of the prostatectomy specimen was suggestive of high-grade spindle cell neoplasm. The margins were focally involved by the tumor. Because of positive margins, the patient underwent adjuvant radiation treatment to postoperative primary tumor bed to a dose of 30 Gy in 15 fractions by conventional fractionation on Halcyon 2.0. The patient tolerated the treatment well with minimal side effects. The patient is symptom-free and disease-free 3 months posttreatment and needs regular and long follow-up.

Leiomyosarcoma of Prostate: A Case Report and Literature Review

Prostate leiomyosarcoma is an extremely rare and very aggressive neoplasm that represents less than 0.1% of primary malignant tumors of the prostate. We present a patient with primary leiomyosarcoma of prostate and examine the cases reported in the literature to discuss the clinical, diagnostic and therapeutic aspects of this rare tumor. Median survival was estimated at 17 months (95% CI 20.7–43.7 months) and the actuarial survival rates at 1, 3 and 5 years were 68%, 34% and 26%, respectively. The only predictors of long-term survival were negative surgical margins and the absence of metastatic disease at presentation. A multidisciplinary approach is necessary for the proper management of this terrible entity.
 Surgery with or without chemotherapy seems to be the main therapeutic method for operable leimyosarcomas, but in general there is no consensus on the best therapeutic approach. Most cases are diagnosed at an advanced stage of the disease. A global multicenter trial is needed to find therapies that would improve the prognosis.

Prostate Leiomyosarcoma: A Rare Misleading Tumor

73 year-old patient present with lower urinary tract symptoms (LUTS) and a low serum prostate specific antigen (PSA) diagnosed with a prostate leiomyosarcoma following a TURP. Afterwards, he was submitted to radical prostatectomy. A multimodal approach with radiotherapy was considered although death occurred less than three months after surgery. Prostate leiomyosarcoma is a rare aggressive tumour with misleading clinical features which may delay the diagnosis. The rarity of prostate sarcomas makes it very difficult to have prospective studies and appropriate clinical research. Therefore, it is of the utmost importance to report its occurrence in order to improve our knowledge of its natural history. There are no guidelines concerning an optimal treatment. When feasible, surgery is the mainstay of treatment. Notwithstanding, recently published data favour multimodal therapies for the treatment of prostatic sarcomas, particularly for locally advanced disease.

Prostatic leiomyosarcoma: A rare and aggressive tumor

Primary prostatic sarcomas of adults are very rare with the most common type being prostatic leiomyosarcoma. They occur in men in their late age with the clinical features similar to that of prostatic carcinoma, so diagnosis can only be made after the resection of prostate and histopathological examination. Histopathologically, they are mitotically active tumors composed of interlacing fascicles and bundles of smooth muscle with areas of necrosis. These tumors have an aggressive clinical course and bad prognosis. Here, we present a case of 58 years male who presented with urinary complaints and lower abdominal pain. After microscopic and immunohistochemical examination of the specimen following transurethral resection of prostate, a final diagnosis of prostatic leiomyosarcoma was made.

Long term follow-up of surgery management of prostate leiomyosarcoma metastasized to the rib: A case report and literature review.

Prostate sarcoma, particularly the pathological type of leiomyosarcoma, is a rare carcinoma, which originated from the interstitial tissue of the prostate. This sarcoma type has a poor prognosis. This disease accounts for ~0.1% of all prostate cancer and it usually occurrs in patients aged between 40 and 78-years-old. Although prostate leiomyosarcoma has a poor prognosis, early treatment of post-operative recurrence and metastases via a whole-body examination and closer follow-up was possible. These measurements may significantly prolong the survival time and improve the quality of life. The present study reported a successful case of surgical management for prostate leiomyosarcoma in the Zigong No. 4 People's Hospital (Sichuan, China) during 1995 until 2015, with post-operative follow-up for 20 years.

P1-31-3 - Radiation-Induced Leiomyosarcoma in Prostate After Brachytherapy for Prostatic Adenocarcinoma

Radiation (RTx) has been employed as a curative therapy for prostatic adenocarcinoma. RTx-induced sarcomas are rare late adverse event, representing less than 0.2% of all irradiated patients. RTx-induced sarcomas are more aggressive tumors than prostatic adenocarcinoma. Herein, we present a case with RTx-induced prostatic leiomyosarcoma after permanent brachytherapy for prostatic adenocarcinoma.A 69-year-old male was diagnosed as localized prostatic adenocarcinoma, and treated by brachytherapy. Dysuria and gross hematuria started to appear six years after brachytherapy. Urethroscopy showed stenosis by a tumor at the prostate. Transurethral prostatectomy was performed for a diagnosis. Based on pathological findings, we diagnosed as leiomyosarcoma of prostate. He was treated with three cycles of neo-adjuvant chemotherapy (CT) consisted with doxorubicin and ifosfamide (AI), and then performed prostatocystectomy with intrapelvic lymphadenectomy. The tumor extended from the prostate and infiltrated the bladder wall and serosa with lymphatic and venous invasion. The surgical margin was negative, and no residual prostatic adenocarcinoma was observed. The proportion of necrotic tumor cells by neo-adjuvant CT was less than 50%. Subsequently, adjuvant CT was offered, but he chose a follow-up without CT. Local recurrence and lung metastasis were detected by computed tomography three months after the surgery. He was treated again with AI. However, CT was not effective and he died six months after the operation. In conclusion, effective treatment strategy for prostatic sarcoma should be developed in the near future, although the clinical feature of prostatic sarcoma remains unclear due to rare incidence.

Leiomyosarcoma of prostate: A rare, aggressive tumor

Leiomyosarcoma of prostate is a rare, aggressive tumor with bizarre presentation at advanced stage. Though definite treatment modalities are not recommended till now, innovative combined multimodality treatment strategies may help to improve the prognosis of patients with this tumor of poor survival rate. Here we report a case of leiomyosarcoma of the prostate which presented with chest metastasis.

Rare metastatic prostatic malignancy: A case report and approach to management

We present a patient with metastatic leiomyosarcoma of the prostate who achieved complete response with chemotherapy. A 70 years old male patient presented with urinary tract symptoms and a prostatic mass. After having been treated as carcinoma prostate, he presented with progressive pelvic mass, lung and bone metastases to our hospital. Repeat biopsy was suggestive of prostatic leiomyosarcoma. He was treated with chemotherapy with the ifosfamide-epirubicin regimen and achieved complete remission on positron emission tomography/computerized tomography after three cycles. He was given a total of six cycles of chemotherapy and continues to be disease-free after 8 months. Although adenocarcinomas are the commonest prostatic malignancies in the elderly, a careful evaluation is essential to rule out alternative diagnoses. Our case report illustrates the potential role of combination chemotherapy in the management of advanced leiomyosarcoma of the prostate. The literature on this entity is reviewed.

Prostatic Leiomyosarcoma –A Rare Case Report With Review Of Literature

Prostatic Leiomyosarcoma –A Rare Case Report With Review Of Literature

Primary leiomyosarcoma of the prostate with lung metastasis: Report of a case diagnosed by fine‐needle aspiration cytology

Prostate leiomyosarcoma is an extremely rare and highly aggressive neoplasm that accounts for less than 0.1% of primary prostate malignancies. Herein, we present a patient with primary leiomyosarcoma of the prostate with lung metastasis diagnosed primarily on fine-needle aspiration cytology. Characteristic cytological features such as small fascicles of spindle cells with blunt-ended nuclei, positivity for desmin and smooth muscle actin along with the radiological features are helpful in the correct diagnosis.

Receptor-regulated Interaction of Activator of G-protein Signaling-4 and Gαi

Activator of G-protein signaling-4 (AGS4), via its three G-protein regulatory motifs, is well positioned to modulate G-protein signal processing by virtue of its ability to bind Galpha(i)-GDP subunits free of Gbetagamma. Apart from initial observations on the biochemical activity of the G-protein regulatory motifs of AGS4, very little is known about the nature of the AGS4-G-protein interaction, how this interaction is regulated, or where the interaction takes place. As an initial approach to these questions, we evaluated the interaction of AGS4 with Galpha(i1) in living cells using bioluminescence resonance energy transfer (BRET). AGS4 and Galpha(i1) reciprocally tagged with either Renilla luciferase (RLuc) or yellow fluorescent protein (YFP) demonstrated saturable, specific BRET signals. BRET signals observed between AGS4-RLuc and Galpha(i1)-YFP were reduced by G-protein-coupled receptor activation, and this agonist-induced reduction in BRET was blocked by pertussis toxin. In addition, specific BRET signals were observed for AGS4-RLuc and alpha(2)-adrenergic receptor-Venus, which were Galpha(i)-dependent and reduced by agonist, indicating that AGS4-Galpha(i) complexes are receptor-proximal. These data suggest that AGS4-Galpha(i) complexes directly couple to a G-protein-coupled receptor and may serve as substrates for agonist-induced G-protein activation.

Primary Prostatic Leiomyosarcoma With Pulmonary Metastases in a Dog

A 6-year-old, intact male Jack Russell terrier was diagnosed with a mass in the caudal abdomen, and ultrasound revealed a large prostatic mass. A total-body computed tomography scan was performed for staging, and lung nodules were detected. Histological examination showed a proliferation of spindle cells arranged in interlacing fascicles. Immunohistochemical staining revealed cells were cytokeratin negative and immunoreactive for vimentin and alpha-smooth muscle actin; cells stained with desmin and S-100 were negative. A diagnosis of primary prostatic leiomyosarcoma with pulmonary metastases was made. This is one of the rare cases of primary prostatic mesenchymal tumor in the canine species.

Leiomyosarcoma of the Prostate: Case Report and Review of 54 Previously Published Cases

Prostate leiomyosarcoma is an extremely rare and highly aggressive neoplasm that accounts for less than 0.1% of primary prostate malignancies. We present a patient with primary leiomyosarcoma of the prostate and review 54 cases reported in the literature to discuss the clinical, diagnostic and therapeutic aspects of this uncommon tumor. Median survival was estimated at 17 months (95% C.I. 20.7–43.7 months) and the 1-, 3-, and 5-year actuarial survival rates were 68%, 34%, and 26%, respectively. The only factors predictive of long-term survival were negative surgical margins and absence of metastatic disease at presentation. A multidisciplinary approach is necessary for appropriate management of this dire entity.

Leiomyosarcoma of the Prostate

Leiomyosarcoma of the Prostate